Methods of detection and removal of rhabdoviruses from cell lines
The present disclosure relates to compositions, methods, mixtures, and kits for detecting the presence of, and for removing, a virus from a product produced in an insect cell. The disclosure also relates to proteins, peptides, polypeptides, drug substances, biological products, vaccine antigens, and virus-like particles that are produced in an insect cell and that are free or substantially free of a virus. The disclosure also relates to compositions, methods, assays, and kits for detecting a rhabdovirus in a sample.
1. A rhabdovirus-free Sf9 or Sf21 insect cell, or a rhabdovirus-free cell passaged therefrom, comprising a biological product.
2. The insect cell of claim 1 , wherein the insect cell is free of a nucleotide sequence having at least 70% homology to SEQ ID NO:1.
3. The insect cell of claim 1 , wherein the insect cell is free of a nucleotide sequence comprising the sequence according to SEQ ID NO: 1.
4. The insect cell of claim 1 , wherein the insect cell is an Sf9 cell.
5. The insect cell of claim 4 , wherein the Sf9 cell is derived from the cell line deposited as ATCC CRL-1711.
6. The insect cell of claim 1 , wherein the cell is passaged from an Sf9 cell derived from the cell line deposited as ATCC CRL-1711.
7. The insect cell of claim 1 , wherein the cell is passaged from the cell line deposited as ATCC CRL-1711.
8. The insect cell of claim 1 , wherein the biological product is a protein, peptide, drug substance, virus-like particle (VLP), antibody, growth factor, polysaccharide, nucleic acid, virus, or vaccine antigen.
9. The insect cell of claim 1 , wherein the biological product is DNA or RNA.
10. The insect cell of claim 1 , wherein the biological product is a recombinant virus for gene therapy.
11. The insect cell of claim 1 , wherein the biological product is a therapeutic protein or an enzyme.
12. The insect cell of claim 1 , wherein the biological product is a protein and the protein is glycosylated.
13. A rhabdovirus-free cell comprising a biological product, wherein the rhabdovirus-free cell is passaged from an Sf9 or Sf21 insect cell.
14. The cell of claim 13 , wherein the cell is free of a nucleotide sequence having at least 70% homology to SEQ ID NO:1.
15. The cell of claim 13 , wherein the cell is free of a nucleotide sequence comprising the sequence according to SEQ ID NO: 1.
16. The cell of claim 13 , wherein the cell is an Sf9 cell.
17. The cell of claim 16 , wherein the Sf9 cell is derived from the cell line deposited as ATCC CRL-1711.
18. The cell of claim 13 , wherein the biological product is a protein, peptide, drug substance, virus-like particle (VLP), antibody, growth factor, polysaccharide, nucleic acid, virus, or vaccine antigen.
19. The cell of claim 13 , wherein the biological product is DNA or RNA.
20. The cell of claim 13 , wherein the biological product is a recombinant virus for gene therapy.
21. The cell of claim 13 , wherein the biological product is a therapeutic protein or an enzyme.
22. The cell of claim 13 , wherein the biological product is a vaccine antigen.
23. The cell of claim 13 , wherein the biological product is a Calicivirus VLP or a Norovirus VLP.
24. The cell of claim 13 , wherein the biological product is a protein and the protein is glycosylated.
25. A rhabdovirus-free Sf9 or Sf21 insect cell, or a rhabdovirus-free cell passaged therefrom.
26. The insect cell of claim 25 , wherein the insect cell is free of a nucleotide sequence having at least 70% homology to SEQ ID NO:1.
27. The insect cell of claim 25 , wherein the insect cell is free of a nucleotide sequence comprising the sequence according to SEQ ID NO: 1.
28. The insect cell of claim 25 , wherein the insect cell is an Sf9 cell.
29. The insect cell of claim 28 , wherein the Sf9 cell is derived from the cell line deposited as ATCC CRL-1711.
30. The insect cell of claim 25 , wherein the cell is passaged from the cell line deposited as ATCC CRL-1711, or is passaged from an Sf9 cell derived from the cell line deposited as ATCC CRL-1711.